GLP-1 for Fatty Liver (MASLD/MASH)

Fatty liver disease and weight are tightly linked — and GLP-1 medications are now a proven treatment for its serious form. Here’s what the science and the 2025 FDA approval actually say.

Verified Jun 2026 · re-checked quarterlyBy the GLP1Zoom editorial teamWe compare, we don’t sell

The short answer

Yes — GLP-1 medications help fatty liver disease. Wegovy (semaglutide) became FDA-approved for MASH with fibrosis in August 2025 (the ESSENCE trial showed ~63% MASH resolution), and tirzepatide showed similar results (~62%, not yet FDA-approved for MASH). The benefit comes mainly from significant weight loss plus metabolic effects. Advanced liver disease needs a clinician’s — ideally a hepatologist’s — guidance.

What is fatty liver disease (MASLD/MASH)?

Fatty liver disease — now called MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) — is excess fat in the liver tied to weight, insulin resistance, and metabolic syndrome. Its inflammatory, scarring form is MASH (formerly NASH), which can progress to fibrosis and cirrhosis. It’s strongly driven by the same factors GLP-1 medications target.

Do GLP-1s treat fatty liver?

The evidence is now strong. In the phase-3 ESSENCE trial, 72 weeks of semaglutide achieved MASH resolution without worsening fibrosis in about 63% of patients — leading to FDA approval of Wegovy for MASH (with F2–F3 fibrosis) in August 2025, only the second drug ever approved for the condition. Tirzepatide’s SYNERGY-NASH trial reached similar resolution rates (up to ~62% at the highest dose). Improvement tracks with weight loss.

Which GLP-1 for fatty liver?

Semaglutide (Wegovy) carries the specific FDA MASH indication; tirzepatide (Zepbound) has comparable trial data and the most weight loss overall. The right choice depends on your liver stage, other conditions, and insurance — compare them in best GLP-1 for weight loss, and decide with your clinician.

How to get evaluated

See a doctor — primary care, a liver specialist, or a licensed telehealth provider that evaluates you online and prescribes if appropriate. If you may have advanced liver disease, involve a hepatologist. Start by comparing providers below or take our 60-second quiz.

References(2)

Our sourcing standards →

Semaglutide in metabolic dysfunction–associated steatohepatitis (ESSENCE)NEJM — NEJM, 2025
FDA approves semaglutide for MASH with fibrosis — AJMC, 2025

Compare GLP-1 providers

Common questions about GLP-1 for fatty liver

Do GLP-1 medications help fatty liver disease?

Yes. In 2025 the FDA approved Wegovy (semaglutide) to treat MASH (the advanced, inflammatory form of fatty liver) with moderate-to-advanced fibrosis — in the ESSENCE trial about 63% of patients had their MASH resolve without worsening fibrosis. Tirzepatide showed similar results in the SYNERGY-NASH trial (~62% at the top dose), though it isn’t yet FDA-approved for MASH. The benefit comes largely from significant weight loss plus metabolic effects.

Is Ozempic or Wegovy approved for fatty liver?

Wegovy (semaglutide 2.4 mg) is FDA-approved for MASH with moderate-to-advanced (F2–F3) fibrosis as of August 2025 — the second drug ever approved for MASH. Ozempic (lower-dose semaglutide for diabetes) is not specifically approved for it, though it’s the same molecule. Treatment should be guided by a clinician, ideally with liver (hepatology) input for advanced disease.

How much does GLP-1 reverse fatty liver?

In trials, the majority of patients on semaglutide or tirzepatide achieved “MASH resolution” (no more active liver inflammation) without their fibrosis getting worse, over roughly 12–18 months. Results are tied to weight loss; more weight lost generally means more liver improvement. It’s not a guaranteed cure, and advanced scarring (cirrhosis) is a different situation.

How do I get a GLP-1 for fatty liver?

Through a doctor — a primary care clinician, a liver specialist, or a licensed telehealth provider that evaluates you online and prescribes if appropriate. If you have signs of advanced liver disease, a hepatologist should be involved. A prescription is required.

Sources & freshness

Reflects the FDA approval of Wegovy (semaglutide) for MASH with moderate-to-advanced fibrosis (August 2025) based on the phase-3 ESSENCE trial (~63% MASH resolution), and tirzepatide’s SYNERGY-NASH results (up to ~62%). Verified 2026-06-30. Educational only, not medical advice.

What is fatty liver disease (MASLD/MASH)?

Do GLP-1s treat fatty liver?

Which GLP-1 for fatty liver?

How to get evaluated